Clinical Trial

A Study of PM8002 (Anti-PD-L1/VEGF) in Combination With Chemotherapy in Patients With ES-SCLC

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
PM8002 is a bispecific antibody targeting PD-L1 and VEGF. This study to evaluate the efficacy and safety of PM8002 in combination with etoposide and platinum in first-line treatment of extensive-stage small cell lung cancer
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2023-04-25; most recent amendment 2025-03-09.
Status change: Recruiting → Active, Not Recruiting 2025-03-09
Status change: Not Yet Recruiting → Recruiting 2024-01-17
Trial Details
NCT Number NCT05844150
Lead Sponsor Biotheus Inc.
Conditions SCLC
Enrollment 50 participants
Start Date 2023-06-01
Primary Completion 2024-05-10 (estimated)
Study Completion 2025-12 (estimated)
Updated on ClinicalTrials.gov 2025-03-12